Compare CVS Health Corp (CVS) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Newmont Corporation — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.29B), while Newmont Corporation trades at $117.94 (market cap $119.64B). The key difference: CVS Health Corp and Newmont Corporation are close in size by market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Newmont Corporation for 58 Days on average.
| CVS | NEM | |
|---|---|---|
Market Cap | $112.29B | $119.64B |
Volume | 7,763,676 | 4,343,460 |
Sector | Health | Basic Materials |
52-Week High | $110.60 | $135.14 |
52-Week Low | $70.08 | $78.63 |
Typical Hold Time | 83 Days | 58 Days |
Enterprise Value | $174.64B | $116.23B |
Dividend Yield | 3.03% | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Newmont (NEM) trades at $113.54, down 2.45% on the day, amid a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has beaten earnings estimates for three consecutive quarters. Revenue grew to $22.67 billion in 2025 with a net income margin of 33.36%, while analyst consensus remains strongly bullish with a $136.83 price target.
The stock presents a compelling value opportunity with a P/E of 14.32 and robust profitability, though near-term technical weakness and gold price volatility pose risks. Upside potential is supported by operational improvements and shareholder returns, but investors must weigh macroeconomic factors affecting the gold sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
